Inhibition of neutral sphingomyelinase 2 impairs HIV-1 envelope formation and substantially delays or eliminates viral rebound

Seung‐Wan Yoo, Abdül Waheed, Pragney Deme, Şehmus Tohumeken, Rana Rais, Matthew D. Smith, Catherine DeMarino, Peter A. Calabresi, Fatah Kashanchi, Eric O. Freed, Barbara S. Slusher, Norman J. HaugheyProceedings of the National Academy of Sciences 2023 · DOI

TL;DR

Researchers have discovered that the enzyme neutral sphingomyelinase 2 (nSMase2) plays a crucial role in HIV-1 assembly and maturation by remodeling the host cell's plasma membrane. Inhibiting nSMase2 leads to the production of non-infectious viral particles and, importantly, significantly delays or even prevents viral rebound in infected mice, suggesting nSMase2 as a promising therapeutic target.

What Problem Does This Paper Address?

HIV-1 assembly and budding are complex processes driven by the viral Gag polyprotein. While we know Gag recruits viral components and directs the virus to bud from the host cell's plasma membrane, the precise mechanisms by which the lipid composition of this membrane is remodeled during this process remain poorly understood. Specifically, how the virus manipulates the membrane's structure to facilitate its own formation and release is a key question. This paper aims to elucidate the role of lipid-modifying enzymes in this process, focusing on sphingomyelinases, which convert sphingomyelin into ceramide, a molecule known to alter membrane properties.

Methods

The study employed a multi-pronged approach:

  • Cell Culture Experiments: Human T-cell lines (H9) and primary human CD4+ T cells were infected with HIV-1.
  • Pharmacological Inhibition: A potent and selective small-molecule inhibitor of nSMase2, PDDC, and its inactive analog, Cmpd-5, were used to block nSMase2 activity.
  • Genetic Knockdown: RNA interference (shRNA) was used to reduce nSMase2 expression.
  • Biochemical Assays: nSMase2 activity was measured, and viral Gag processing was assessed via Western blotting.
  • Electron Microscopy: The morphology of HIV-1 virions was examined to identify structural defects.
  • Lipidomics: The lipid composition of HIV-1 virions and extracellular vesicles (EVs) was analyzed using mass spectrometry.
  • In Vivo Studies: HIV-1-infected humanized mouse models (NOD/SCID/IL2Rc-null and BLT mice) were treated with PDDC or antiretroviral therapy (ART).
  • Viral Load Measurement: Plasma HIV-1 RNA levels were quantified using qRT-PCR and ELISA.
  • Cell Viability and Apoptosis Assays: Flow cytometry was used to assess the viability and apoptotic markers of infected and uninfected cells.
  • Co-immunoprecipitation: To investigate protein-protein interactions, nSMase2 and Gag were tested for physical association.

Datasets

Not explicitly discussed as "datasets" in the traditional machine learning sense. The study utilized:

  • HIV-1 strains: HIV-1 RF and HIV-1 MN were used for cell culture experiments, and HIV-1 ADA was used in mouse models.
  • Cell lines: H9 T-cell line and TZM-bl cells (for reporter assays).
  • Primary cells: Human CD4+ T cells.
  • Humanized mouse models: NOD/SCID/IL2Rc-null (NSG) mice and Bone Marrow-Liver-Thymus (BLT) mice.

Key Insights and Ideas

  • nSMase2 is a key player in HIV-1 assembly: The study provides strong evidence that nSMase2 directly interacts with HIV-1 Gag and is essential for proper viral envelope formation and maturation.
  • Ceramide generation is critical: nSMase2's enzymatic activity, which produces ceramide, appears to be the mechanism by which it remodels the plasma membrane for viral assembly.
  • Inhibition leads to defective virions: Blocking nSMase2 results in the production of misshapen, non-infectious HIV-1 particles with incomplete Gag lattices.
  • nSMase2 is packaged into virions: The enzyme itself is found within the released HIV-1 particles, suggesting a role beyond just host cell membrane modification.
  • Therapeutic potential against viral rebound: The most striking finding is that inhibiting nSMase2 in infected mice not only suppressed viral loads but also prevented viral rebound after treatment withdrawal, a critical challenge in HIV therapy.
  • Selective killing of infected cells: PDDC treatment appears to selectively induce cell death in actively replicating HIV-1-infected cells, offering a potential strategy to eliminate viral reservoirs.

Key Results

  • Increased nSMase2 expression and activity: HIV-1 infection of H9 cells led to a time-dependent increase in nSMase2 expression and activity, along with elevated levels of ceramides.
  • Defective virion production: Inhibition of nSMase2 with PDDC or genetic knockdown resulted in HIV-1 virions with irregularly shaped envelopes and immature Gag lattices, leading to a severe reduction in infectivity (e.g., ~75% reduction in infectivity in Figure 3E).
  • Altered virion lipid composition: PDDC treatment altered the lipid content of HIV-1 virions, increasing sphingomyelin and decreasing ceramide levels compared to EVs.
  • Suppression of viral load in vivo: In humanized mice, PDDC treatment caused a linear decrease in plasma HIV-1 viral loads, with many mice becoming undetectable.
  • Prevention of viral rebound: Crucially, in mice that achieved undetectable viral loads with PDDC, viral rebound was significantly delayed or eliminated for at least 4 weeks after treatment cessation, unlike ART-treated mice which showed rapid rebound.
  • Selective cell death: PDDC treatment selectively reduced the viability of HIV-1-infected cells, inducing apoptosis, while leaving uninfected cells largely unaffected.

Limitations and Future Work

The authors acknowledge several areas for future investigation:

  • Mechanism of nSMase2-Gag interaction: The precise timing and mechanism by which HIV-1 Gag interacts with nSMase2, and whether this interaction is sufficient to activate the enzyme, are still under investigation.
  • Role of nSMase2 within virions: The specific function of nSMase2 packaged within HIV-1 virions and its necessity for viral maturation require further study.
  • Viral escape mechanisms: It is unknown whether HIV-1 can develop resistance to nSMase2 inhibition.
  • Targeting latent reservoirs: A key question is whether latently infected cells, which are not actively replicating, can be targeted for elimination by nSMase2 inhibition.
  • Detailed mechanism of cell death: While evidence suggests apoptosis, the exact molecular pathways by which PDDC kills HIV-1-infected cells need further elucidation.

Summary updated

Abstract

Although HIV-1 Gag is known to drive viral assembly and budding, the precise mechanisms by which the lipid composition of the plasma membrane is remodeled during assembly are incompletely understood. Here, we provide evidence that the sphingomyelin hydrolase neutral sphingomyelinase 2 (nSMase2) interacts with HIV-1 Gag and through the hydrolysis of sphingomyelin creates ceramide that is necessary for proper formation of the viral envelope and viral maturation. Inhibition or depletion of nSMase2 resulted in the production of noninfectious HIV-1 virions with incomplete Gag lattices lacking condensed conical cores. Inhibition of nSMase2 in HIV-1-infected humanized mouse models with a potent and selective inhibitor of nSMase2 termed PDDC [phenyl(R)-(1-(3-(3,4-dimethoxyphenyl)-2, 6-dimethylimidazo[1,2-b]pyridazin-8-yl) pyrrolidin-3-yl)-carbamate] produced a linear reduction in levels of HIV-1 in plasma. If undetectable plasma levels of HIV-1 were achieved with PDDC treatment, viral rebound did not occur for up to 4 wk when PDDC was discontinued. In vivo and tissue culture results suggest that PDDC selectively kills cells with actively replicating HIV-1. Collectively, this work demonstrates that nSMase2 is a critical regulator of HIV-1 replication and suggests that nSMase2 could be an important therapeutic target with the potential to kill HIV-1-infected cells.
BibTeX
@inproceedings{yoo2023inhibition,
  author = {Seung‐Wan Yoo and Abdül Waheed and Pragney Deme and Şehmus Tohumeken and Rana Rais and Matthew D. Smith and Catherine DeMarino and Peter A. Calabresi and Fatah Kashanchi and Eric O. Freed and Barbara S. Slusher and Norman J. Haughey},
  title = {{Inhibition of neutral sphingomyelinase 2 impairs HIV-1 envelope formation and substantially delays or eliminates viral rebound}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2023},
  doi = {10.1073/pnas.2219543120},
}
Figure